Results 1 to 3 of 3

Thread: Trump Names Moncef Slaoui, Operation Warp Speed Chief Advisor

  1. #1

    Trump Names Moncef Slaoui, Operation Warp Speed Chief Advisor

    May 15, 2020

    Moncef Slaoui (born 1959) is a Moroccan-born American-Belgian researcher and former head of GlaxoSmithKline's vaccines department. He worked at the company for thirty years, retiring in 2017. On May 15, 2020, it was announced that Slaoui would manage the U.S. government's development of a vaccine used to treat Coronavirus disease, dubbed "Operation Warp Speed."

    On May 15, President Donald Trump officially announced Operation Warp Speed, a project to develop and deliver 300 million doses of a vaccine for the coronavirus disease 2019 by January 2021.

    Operation Warp Speed was managed by the White House senior adviser Jared Kushner with the support of the United States Department of Defense and the United States Department of Health and Human Services.

    Slaoui, who called the 12-to-18 month time frame "very aggressive" but "achievable", was named as the chief adviser of the project, working alongside chief operating officer and four-star general Gustave F. Perna.

    To avoid a conflict of interest, Slaoui resigned from the board of the Massachusetts-based biotech firm Moderna, which had been developing a vaccine for the coronavirus.

    Slaoui also sits on the boards of SutroVax, the Biotechnology Innovation Organization, the International AIDS Vaccine Initiative, and the PhRMA Foundation.


    https://en.wikipedia.org/wiki/Moncef_Slaoui
    “The right to life is the source of all rights—and the right to property is their only implementation. Without property rights, no other rights are possible. Since man has to sustain his life by his own effort, the man who has no right to the product of his effort has no means to sustain his life. The man who produces while others dispose of his product, is a slave.”

    An Agorist Primer



  2. Remove this section of ads by registering.
  3. #2
    I'll add this to this thread also:

    Who is the New Leader of Operation Warp Speed?



    President Trump announced that Moroccan-born Dr. Moncef Slaoui, the former chairman of GlaxoSmithKline’s vaccines division, would serve as Chief Adviser for Operation Warp Speed, the administration’s project to fast-track a COVID-19 vaccine.

    Slaoui will work together with General Gustave Perna, who was appointed as the Chief Operation Officer for Operation Warp Speed.

    Dr. Slaoui will become yet another member of President Trump’s medical advisors with strong ties to Bill Gates. During his days as chairman of GlaxoSmithKline’s vaccines division, Slaoui was instrumental in developing the vaccine Mosquirix, a malaria vaccine for use in tropical and subtropical areas. (Source.)

    The drug was funded through The Bill and Melinda Gates Foundation.

    In an article published on the website The Borgen Project, titled Mosquirix: New Malaria Vaccine Approved, author Katie Pickle stated in 2015 that:

    Thanks to the efforts of GlaxoSmithKline and the generous support of The Bill and Melinda Gates Foundation, the world’s first malaria vaccine has been approved by regulators at the European Medicine Agency.

    GSK worked with the PATH Malaria Vaccine Initiative to create the immunization, which is meant for use in tropical and subtropical areas where the illness is prevalent and largely uncontrolled. Called RTS,S in its experimental stages, Mosquirix is designed for children 6-17 months old whose immune systems are still developing.

    The Bill and Melinda Gates Foundation contributed over $200 million to the drug’s research and development, and GSK is optimistic that it will be effective in reducing incidences of malaria in Sub-Saharan Africa where cases of malaria caused by the parasite are most common.
    The vaccine is not without its short-comings, as Pickle reported:

    The main road bump for Mosquirix? Distribution. The vaccine may exist, but to the young children in Africa who need it, it may as well be a fantasy.

    The question is whether the distribution of the vaccination to areas where it is needed is worth the time and the money. The World Health Organization is skeptical of the feasibility of Mosquirix’s implementation and has not yet issued a recommendation for its use.

    There is a reason that most vaccines are not made against parasites – unlike bacteria or a virus, a parasite has a complicated life cycle that transports it around the body. Parasites like those that cause malaria can remain living in the body for years.
    Almost 5 years later now, the World Health Organization has approved the use of Mosquirix in African countries, but the problems remain. A report in JSTOR Daily last month (April 2020) states:

    After 30 years of work, the first malaria vaccine was rolled out in Africa in 2019, despite concerns about it efficiency and safety. Named Mosquirix, it works by stimulating an immune response against a protein found on the sporozoites’ surface. Set up by WHO, the pilot effort aimed to vaccinate hundreds of thousands of children in Malawi, Ghana, and Kenya.
    Since leaving his position as the chairman of the vaccine division at GSK, Dr. Slaoui has taken on roles at several other biotech medical firms, usually sitting on their board of directors.

    Government watchdog groups were quick to point out the obvious conflicts of interest with Dr. Slaoui receiving funds to develop a COVID-19 vaccine, including sitting on the board with the same pharmaceutical company working with Dr. Anthony Fauci that has received hundreds of billions of dollars to develop a COVID-19 vaccine, Moderna, Inc.

    Common Dreams Staff Writer Julia Conley writes:

    Government watchdog Public Citizen on Thursday condemned the Trump administration’s reported appointment of a former pharmaceutical executive to the White House’s task force aimed at swiftly developing a Covid-19 vaccine…

    The administration named Moncef Slaoui, former head of GlaxoSmithKline’s vaccine division and a venture capitalist in the pharmaceutical field, to act as chief adviser for the program, called “Operation Warp Speed.”

    Slaoui worked at GlaxoSmithKline for 30 years until 2017, and since then has sat on the boards of a number of pharmaceutical firms which are now researching potential vaccines for the coronavirus—leaving the former executive with what Public Citizen called “blatant financial conflicts of interest.”

    Currently a partner at pharmaceutical investment firm Medicxi, Slaoui has earned $490,000 as a board member at Moderna, Inc. and also sits on the board of Lonza Group AG, a Swiss company which is contracting with Moderna to find a Covid-19 vaccine. His former employer, GlaxoSmithKine, is also working to develop an immunization.
    Dr. Slaoui also has ties to Alphabet, the parent company of Google.

    As a partner at Medicxi, a venture capital group that invests in pharmaceutical industry companies, he sits on the board of several companies that Medicxi has invested in, including serving as chairman of the board at Galvani Bioelectronics, a company formed in 2016 with funding from GSK and Google. (Source.)

    As we have previously reported here at Health Impact News, Google is now a pharmaceutical company, and a major player in the biotech industry, which may explain why they suppress anything negative regarding vaccines in their search results.

    Galvani Bioelectronics is dedicated to the development of bioelectronic medicines – a new class of medicines consisting of miniaturised, implantable devices. (Source.)

    While serving as chairman of the vaccine division of GSK, Dr. Slaoui helped develop several highly profitable vaccines, including:

    • Rotarix®, to prevent infantile rotavirus gastroenteritis
    • Synflorix®, to prevent pneumococcal disease
    • Mosquirix, to prevent plasmodium malaria disease
    • Shingrix, to prevent shingles
    • Cervarix®, an HPV vaccine to prevent cervical cancer

    Cervarix is GSK’s equivalent to Merck’s Gardasil HPV vaccine, which has been linked to serious injuries to young girls, including infertility.

    Dr. Moncef Slaoui also sits on the board of the International AIDS Vaccine Initiative. (Source.)

    As we have previously reported, especially through the investigative work of Robert F. Kennedy, Jr., Chairman of the Children’s Health Defense, Bill Gates, Dr. Anthony Fauci, Dr. Deborah Birx, and CDC Director Robert Redfield all have a long history of working together on trying to develop an HIV/AIDS vaccine.

    And now we can add Dr. Moncef Slaoui to this team, all being employed by the U.S. Federal Government (except for Bill Gates who does not need to be employed by anyone) to fast-track the COVID-19 vaccine, that President Trump just announced will be deployed by the U.S. military.

    Source.
    There is no fear in love, but perfect love casts out fear. For fear has to do with punishment, and whoever fears has not been perfected in love.
    (1 John 4:18)

  4. #3
    Quote Originally Posted by PAF View Post
    May 15, 2020

    Moncef Slaoui (born 1959) is a Moroccan-born American-Belgian researcher and former head of GlaxoSmithKline's vaccines department. He worked at the company for thirty years, retiring in 2017. On May 15, 2020, it was announced that Slaoui would manage the U.S. government's development of a vaccine used to treat Coronavirus disease, dubbed "Operation Warp Speed."

    On May 15, President Donald Trump officially announced Operation Warp Speed, a project to develop and deliver 300 million doses of a vaccine for the coronavirus disease 2019 by January 2021.

    Operation Warp Speed was managed by the White House senior adviser Jared Kushner with the support of the United States Department of Defense and the United States Department of Health and Human Services.

    Slaoui, who called the 12-to-18 month time frame "very aggressive" but "achievable", was named as the chief adviser of the project, working alongside chief operating officer and four-star general Gustave F. Perna.

    To avoid a conflict of interest, Slaoui resigned from the board of the Massachusetts-based biotech firm Moderna, which had been developing a vaccine for the coronavirus.

    Slaoui also sits on the boards of SutroVax, the Biotechnology Innovation Organization, the International AIDS Vaccine Initiative, and the PhRMA Foundation.


    https://en.wikipedia.org/wiki/Moncef_Slaoui

    I am sure after he has gone working for Trump, he will not ever go back to Moderna. He will retire and not ever profit the new liberty enabling vaccines



Similar Threads

  1. Replies: 9
    Last Post: 04-30-2020, 12:58 PM
  2. Replies: 5
    Last Post: 09-19-2019, 08:45 PM
  3. Replies: 21
    Last Post: 09-22-2011, 08:40 PM
  4. Donald Trump Trump's Chief Advisor a Democrat who voted for Obama
    By ronpaulhawaii in forum 2012 Presidential Election
    Replies: 0
    Last Post: 04-27-2011, 05:14 PM
  5. Bono MegaDouche has now entered light-speed hyperdrive warp factor 10
    By Mitt Romneys sideburns in forum Open Discussion
    Replies: 13
    Last Post: 01-06-2010, 02:51 PM

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •